Aptahem AB (publ) can announce today that the company’s board has finalized a revised development plan for the drug candidate Apta-1. The new development plan was established together with the company’s scientific advisory board who assessed Apta-1’s pharmacological properties....
Read MoreAptahem AB (publ) can announce today that it has entered into a production agreement with BioSpring, a world-leading producer of oligonucleotides. BioSpring has been contracted to manufacture the substance in drug candidate Apta-1 for the company’s preclinical and upcoming...
Read MoreAptahem (publ) can today announce a positive outcome from a study performed in collaboration with Hooke Laboratories (US). The study evaluated the pharmaceutical candidate Apta-1 in a clinically relevant model for sepsis which showed a significant improvement in survival...
Read MoreAptahem’s preclinical programme is proceeding with the gradual collection of data on the Apta-1 effect profile, while the work on the company’s clinical development is proceeding in consultation with external experts. Dialogue with opinion leaders and potential partners has...
Read MoreAptahem can today announce that it has entered into an agreement with lecturer and registered practitioner Anders Bylock, a well-known expert on issues related to cardiovascular treatment including pre-clinical development, clinical trials and regulatory submissions. Dr Bylock will provide...
Read MoreQuintilesIMS publish updates from Aptahem in their newsletter Drug News in December 2016 (see page 15). Aptahem’s CEO Mikael Lindstam presented the information at Bio Europe in Cologne in November 2016. Open Drug News For further information: Mikael Lindstam,...
Read MoreIn November 2016 Smith & Franklin published an article about aptamer. Read the article. For further information: Mikael Lindstam, CEO Aptahem AB Tel: + 46 (0)766-33 36 99 E-mail: ml@aptahem.com About Aptahem Aptahem is developing drug candidates for the...
Read MoreAptahem, together with its US partner Hooke Laboratories in Boston, conducted preclinical studies on the anti-inflammatory effects of the drug candidate Apta-1 compared with Dexamethasone, one of the worldwide most prescribed drugs for inflammatory diseases. The studies indicate a...
Read MoreAptahem announce that the results from studies carried out over recent months’, in a series of targeted animal studies, show that its lead compound APTA-1 demonstrates a positive effect on a number of key features related to the coagulation...
Read MoreAptahem today announced that an extensive collaboration has begun with the Nencki Institute of Experimental Biology. Aptahem and various expert groups within the Institute will jointly examine the effects of the company’s developmental drug candidate, APTA-1. The Nencki Institute...
Read More